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Introduction: The incidenceof pulmonaryhypertension (PH)
in pediatric patients after hematopoietic stem cell transplant
(SCT) is not known. PH is likely underdiagnosed in these
patients due to its non-speciﬁc presentation. We have
observed PH in critically ill SCT patients especially thosewith
transplant associated thromboticmicroangiopathy (TA-TMA).
Hence our goal was to determine the baseline incidence and
to establish the value of routine screening for PH after SCT
Hypothesis: PH occurs in pediatric patients after SCT and
echocardiographic screening may be of value in allowing
prompt diagnosis and intervention.
Methods: A multi-disciplinary practice guideline was
implemented in January 2012 requiring screening for PH in
SCT patients after transplant. All children had pre-transplant
echocardiography as well as echocardiography screening on
days +7, +30, and +100 after SCT, or at the time of ICU
admission if admitted to intensive care unit for known PH,
TA-TMA, respiratory or cardiovascular failure. Echocardiog-
raphy was repeated in 7 to 14 days if results were abnormal.
Patients were stratiﬁed as being “at risk” for, or having PH if
their right ventricular (RV) pressure was estimated at 35-49%
or >50% of systolic blood pressure, respectively.
Results: During an 8 month period, a total of 59 patients
were screened for PH (56 receiving allogeneic and 3
receiving autologous transplants), including 48 consecutive
SCT patients completing 100 days of scheduled screening
and 26 patients screened upon admission to the PICU. Fifteen
patients overlapped the two groups (screened both per
schedule on the ﬂoor and on admission to ICU). Fifteen
patients (25%) were determined to be “at risk” for PH, while 4
(7%) developed PH. Of the 48 patients screened during the
ﬁrst 100 days, 12 (25%) were determined to be “at risk”while
2 (4%) developed PH. Of the 26 patients admitted to the PICU,
7 (27%) were determined to be “at risk” while 4 (15%)
developed PH. Four patients admitted to the ICU received
speciﬁc therapy for PH with one requiring an atrial septos-
tomy for systemic RV pressure and associated low cardiac
output. The median time from transplant to abnormalechocardiography was 13 days. Elevated RV pressure was
signiﬁcantly associated with a diagnosis of TA-TMA (p¼ 0.03)
and presence of an oxygen requirement (p¼ 0.001).
Conclusions: PHmay occur following pediatric SCT. Targeted
echo screening of children, especially thosewith TA-TMA and
unexplained hypoxemia, may be beneﬁcial in detecting PH.
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NK cell transplantation has been increasingly used to
treat cancers that are resistant to chemotherapy. However,
not all cancers are susceptible to NK cell killing. The preva-
lence and mechanisms of NK cell resistance have not been
well elucidated. Because NKG2D is a major activating
receptor on NK cells, we sought to determine the speciﬁc role
of NKG2D pathway in tumor cell recognition. Herein, we
comprehensively assessed 20 cancer cell lines representing
a broad array of pediatric cancers. We found that only 30% of
them expressed high level of NKG2D ligands and were
susceptible to NK cell killing. The dependency on NKG2D
pathway in these NK susceptible cells was conﬁrmed by anti-
NKG2D antibody blocking experiments. For the 70% of cell
lines that were resistant to NK cells, 65% were due to
silencing of NKG2D ligand expression, whereas 35%were due
to insufﬁcient NKG2D activation. For the former cell lines,
NKG2D ligand expression was found to be downregulated at
the mRNA and/or protein level. By histone acetylation and/or
proteasome modulation, these regulatory checkpoints could
be circumvented to obtain sufﬁcient surface expression of
NKG2D ligands to overcomeNK resistance. For the cancer cell
lines that were NK resistant despite a high NKG2D ligand
expression, KIR inhibition was found to override NKG2D
activation in 80% of these cancers. MHC blockade success-
fully increased NK susceptibility of these cell lines. In the
remaining 20%, downregulation of ICAM-1 was responsible
for NK resistance. We conclude that NKG2D is the primary
pathway for tumor cell recognition in NK susceptible tumors.
Evasion of the NKG2D pathway is common through NKG2D-
ligand silencing, KIR inhibition, or inadequate expression of
adhesion molecules to mediate immune-synapse formation.
Because these resistance mechanisms are readily amenable
to therapeutic alteration, NK cell transplantation holds
promise for future cancer therapy.
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Background: Sickle cell anemia (SCA) is a chronic hemolytic
anemia with high morbidity and premature mortality.
Currently, the only available cure for SCA is allogeneic
Table
Features at Diagnosis
Stratum A Stratum B
n ¼ 37 n ¼ 13
Age, days 34 (0 - 304) 74 (0 - 4916)
Gender (M / F) 28 / 9 4 / 9
Trigger of Dx
FH 27% 15%
NBS 32% 8%
Abstracts / Biol Blood Marrow Transplant 19 (2013) S150eS166 S161hematopoietic stem cell transplantation (HSCT). Transplant-
associated risks are one of many barriers to the widespread
use of HSCT for SCA. Over 20 years ago, Kodish et al reported
on parent attitudes towards HSCT for their childrenwith SCA.
Since the risks of matched sibling donor HSCT for SCA are
now better deﬁned and community awareness of HSCT as
a therapeutic option has increased, parent and patient
perceptions of HSCT may have changed.
Methods: To assess current attitudes toward HSCT, we con-
ducted a survey of parents of childrenwith SCA (Hgb SS or S-B0
thal) and teenagers with SCA by using questions based on the
standard reference gamble paradigmandbycomparing survey
responses between African (A) and African American parents
(AA) and between parents and their adolescent children. SCA
severity was assessed based on their self-reported history of
sickle cell disease related complications and hospitalizations.
Results: 89 parents and adolescents (54 parents, 3 patients
and 16 parent-adolescent dyads) were surveyed after
a discussion of the process and outcomes of HSCT and its
attendant risks. 72% of respondents were willing to accept >
5% risk of mortality. 57% of respondents were willing to
accept a risk of 10% or more GVHD. 20/89 (22%) respondents
were unwilling to accept any risk of mortality or GVHD. Risk
averseness did not differ amongst respondents of A or AA
origin. There was no correlation between self reported SCA
severity and acceptance of higher mortality or GVHD risk.
56% of respondents were willing to accept infertility post
BMT regardless of SCA severity or country of origin. Of those
whowerewilling to accept at least a 5% risk of mortality, 75%
were willing to accept a GVHD risk of at least 10%.
Conclusions: These data suggest that the majority of parents
and adolescents are willing to accept the current morbidity
and mortality risks associated with matched sibling HSCT to
achieve a cure of SCA regardless of disease severity. Although
attitudes towards HSCT for SCA have changed over the last 2
decades, there are still signiﬁcant numbers of parents and
adolescents who are unwilling to accept any risk of mortality
or GVHD in order to cure their SCA.Infection 38% 54%
Other 3% 23%
Maternal Engraftment 53% 0%
Autoimmunity 3% 42%
FTT 24% 33%
ALC 1175 (3 - 10120) 1078 (700- 3700)
CD3 6 (0-8898) 1918 (45 - 6589)
CD4 4 (0 - 1307) 474 (31 - 2138)
CD4/CD45RA 0 (0 - 57) 43 (0 - 474)
CD4/CD45RO 1 (0 - 155) 1035 (196 - 1975)
CD8 4 (0 - 750) 78 (0 - 900)
PHA (% lower limit nl) 0 (0 - 20) 12 (0 - 126)
TRECs (#/uL) 0 (0 - 11) 0
B Cells: B+ Phenotype 1171 (164 - 3847);
n ¼ 29
2 (0 - 822)
B- Phenotype 7 (0 - 186); n ¼ 8
IgG (mg/dL), pre-IVIG 539 (0 - 928) 608 (371 - 1030)
IgM (mg/dL) 10 (0 - 89) 13 (0 - 95)
IgA (mg/dL) 7 (0 - 25) 7 (0 - 165)
IgE (IU/mL) 2 (0 - 79) 445 (0 - 20400)
NK Cells: NK+ Phenotype 266 (28 - 939);
n ¼ 12
282 (32 - 734)
NK- Phenotype 16 (0 - 407);
n ¼ 25
IL-2RG 19 0
JAK3 2 1
RAG-1/2 5 7
Artemis 0 1
IL-7R 3 0
CD3d 3 0
ADA 3 0
AK2 0 1
Unknown 1 3
Numbers ¼ median (range); Cells ¼ (x 106/L)93
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ThePIDTCconsists of 32 centers inNorthAmerica that care
for patients with PID. The 6901 study's hypothesis is that the
analysis of uniform data on patients with SCID will identifythose variables that contribute to thebest outcomes following
treatment.Wereportbaseline clinical, immunologic&genetic
features of the 1st 50 patients enrolled & the initial therapies
that they received, to summarize for the ﬁrst time the current
practice in the diagnosis & treatment of SCID.
From 8/2010 - 5/2012 patients with suspected SCID
underwent work-up and therapy per local center practices.
After consent, diagnostic information was reviewed by the
eligibility and stratiﬁcation panel. Stratum A is classic SCID.
Stratum B is leaky SCID, Omenn Syndrome or Reticular
Dysgenesis. HCT details were obtained from the CIBMTR.
Presenting features of the1st 50patients are shown(Table).
92% hadmutations in a known SCID gene. Those diagnosed by
newborn screen (NBS) or family history (FH) were younger
than those diagnosedby clinical signs (median 15 vs.181days;
P0.0001)andwent toHCTat amedianof67daysvs. 214days
(P  0.0001), though there was no difference in time from
diagnosis to HCT (median 56 vs. 43 days; P ¼ 0.28). 92% were
treated with HCT at a median of 25 days from diagnosis for
matched related (n ¼ 7) or 29 days mismatched related
(n¼ 12) donors, vs. 61 days for unrelated adult (n ¼ 13) or 60
days for cord blood (n ¼ 14) donors (P ¼ 0.02). Conditioning
was none (n ¼ 10), serotherapy alone (n ¼ 4); reduced inten-
sity (n¼ 9), or myeloablative (n¼ 23). 3 patients were treated
with gene therapy & 1 with enzyme-replacement.
Future directions include continued enrollment with
a goal of >250 patients & analysis of short and long-term
outcomes of therapy to identify which factors are beneﬁcial
